Pluristem Therapeutics Inc. (PSTI)

0.56
NASDAQ : Health Technology
Prev Close 0.56
Day Low/High 0.56 / 0.58
52 Wk Low/High 0.50 / 1.38
Avg Volume 627.00K
Exchange NASDAQ
Shares Outstanding 149.74M
Market Cap 84.23M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)
New Published Data Show Pluristem's PLX Cells Protect Neurons

New Published Data Show Pluristem's PLX Cells Protect Neurons

PLX Cells Could Potentially be Used to Treat Stroke or Other Injuries to the Nervous System Attributable to Low Oxygen Levels

Pluristem's Dr. Ohad Karnieli To Present At Two Upcoming Scientific Conferences

Pluristem's Dr. Ohad Karnieli To Present At Two Upcoming Scientific Conferences

Presentations to Focus on Pluristem's Industry-Leading Expertise in 3D Cell Culturing and Cell Expansion Technologies

Pluristem Granted Patents In Australia And New Zealand For Use Of Placental Cells In The Treatment Of Multiple Indications

Pluristem Granted Patents In Australia And New Zealand For Use Of Placental Cells In The Treatment Of Multiple Indications

Indications Include Orthopedic, Nerve Injury and Neurodegenerative Diseases

Case Western Reserve University To Study Pluristem's PLX-RAD Cells In Umbilical Cord Blood Transplants For The Treatment Of Blood Cancers And Genetic Diseases

Case Western Reserve University To Study Pluristem's PLX-RAD Cells In Umbilical Cord Blood Transplants For The Treatment Of Blood Cancers And Genetic Diseases

The Study Will Determine Whether Pluristem's Second Major Product Line May Help Cord Blood Cells to Successfully Replace Damaged Bone Marrow

Pluristem Advances Its Second Major Cell Therapy Product Line From Development To Large-Scale Manufacturing

Pluristem Advances Its Second Major Cell Therapy Product Line From Development To Large-Scale Manufacturing

Marks Second Major Cell Therapy Product Line Developed on Company's PLX Platform; PLX-RAD Cells Address Multiple Indications Associated With Bone Marrow Deficiency

Pluristem To Deliver Scientific Presentations At 3rd International Placenta Stem Cell Society Meeting

Pluristem To Deliver Scientific Presentations At 3rd International Placenta Stem Cell Society Meeting

Sharing Insights and Knowledge of the Unique Immune-Privileged Properties and Mechanism of Action of PLX Cells

Israel's Ministry Of Health Approves Pluristem's Commercial-Scale 3D Cell Manufacturing Process Used At Its New Haifa Facility

Israel's Ministry Of Health Approves Pluristem's Commercial-Scale 3D Cell Manufacturing Process Used At Its New Haifa Facility

This Follows Clearances From U.S., E.U., German, and South Korean Regulators

Pluristem To Host Investor Breakfast And Webcast On July 23 In New York City

Pluristem To Host Investor Breakfast And Webcast On July 23 In New York City

Key Opinion Leader Dr. Baha Sibai Will Discuss Preeclampsia, a Disease That Costs the U.S. $7 Billion Annually

Pluristem Initiates South Korean Arm Of Multinational Phase II Intermittent Claudication Trial

Pluristem Initiates South Korean Arm Of Multinational Phase II Intermittent Claudication Trial

Trial Now Active in 13 Clinical Centers in 4 Countries

Pluristem's Ohad Karnieli To Deliver A Plenary Presentation On Cell Therapy Manufacturing At ISUS 2014 Conference

Pluristem's Ohad Karnieli To Deliver A Plenary Presentation On Cell Therapy Manufacturing At ISUS 2014 Conference

Pluristem to Share Insights on Emerging Markets and Its Industry-Leading Cell Manufacturing Methods With Audience of Bio-Manufacturing Experts

Pluristem Selects Rotator Cuff Repair As New Orthopedic Indication

Pluristem Selects Rotator Cuff Repair As New Orthopedic Indication

PLX Cells Offer Potential as First Off-the-Shelf Product for Muscle and Tendon Regeneration

Pluristem Granted Patent In Russia For Treatment Of Inflammatory Bowel Disease Using Placenta-Derived Cells

Pluristem Granted Patent In Russia For Treatment Of Inflammatory Bowel Disease Using Placenta-Derived Cells

PLX Cells Shown to be a Potentially Effective Treatment

Pluristem Move Forward In The Orthopedic Area With The Support Of Key Opinion Leaders

Pluristem Move Forward In The Orthopedic Area With The Support Of Key Opinion Leaders

Evaluating Several Orthopedic Indications for Company's PLX-PAD Cell Therapy

Pluristem Receives Clearance From South Korea To Use PLX Cells Manufactured At Its New Facility In Its Advances Studies

Pluristem Receives Clearance From South Korea To Use PLX Cells Manufactured At Its New Facility In Its Advances Studies

CEO Zami Aberman to Present at BIO KOREA 2014 on May 29

Pluristem To Present At World Stem Cells Regenerative Medicine Congress 2014 In London

Pluristem To Present At World Stem Cells Regenerative Medicine Congress 2014 In London

CEO Zami Aberman to Present Case Study on Placenta-Based Cell Therapies and Participate in Panel on Cell Therapy Funding and Deal Making

Pluristem To Be Added To New TA Tech-Elite Stock Index In Israel

Pluristem To Be Added To New TA Tech-Elite Stock Index In Israel

Pluristem to Comprise 2% of the Index Scheduled to Launch on May 11, 2014

Pluristem's Manufacturing Facility Approved By European Auditors For Phase III Trials

Pluristem's Manufacturing Facility Approved By European Auditors For Phase III Trials

Company Can Expand Into, and Advance Its Clinical Trials, in Any European Union Member Nation

Pluristem And The Alliance For Regenerative Medicine Advocate For Industry Advancement In Washington D.C.

Pluristem And The Alliance For Regenerative Medicine Advocate For Industry Advancement In Washington D.C.

Key Meetings With Congress and the FDA With a Goal Towards More Rapidly Bringing Breakthrough Cell Therapies to Market

TheStreet Quant Rating: D- (Sell)